Hemodynamic Monitoring Systems Market Analysis

Global Hemodynamic Monitoring System Market Overview

Hemodynamic Monitoring System Market Size was valued at USD 0.98 billion in 2022 and is projected to grow from USD 1.04 Billion in 2023 to USD 8.79 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.5% during the forecast period (2023 - 2032). The main market drivers that are anticipated to be the rising prevalence of lifestyle-related diseases such as diabetes, obesity, stroke, and hypertension. The prevalence of heart problems, which necessitates a routine evaluation of the hemodynamic parameters, is predicted to rise due to these diseases.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In October 2023, Masimo announced that it has obtained CE mark approval for its LiDCO board-in-cable (BIC) module used in hemodynamic monitoring. The business based in Irvine, California, developed LiDCO BIC to be compatible with multi-patient monitoring platforms like the Masimo Root Patient Monitoring and Connectivity Hub. Clinicians may effortlessly integrate LiDCO hemodynamic monitoring, along with the company's adaptable PulseCO algorithm, into their Root patient monitoring centers. LiDCO is compatible with any type of pressure transducer and allows for hemodynamic monitoring in conjunction with other supported parameters, eliminating the need for a separate hemodynamic monitoring device. According to Masimo, the module provides a wide range of features, including guided procedures for assessing fluid responsiveness, detailed trending data, and notifications for beat-by-beat pressure analysis. These features can be shown in customized settings for each patient. Integrating LiDCO's sophisticated hemodynamic monitoring with Masimo Root has the potential to offer a comprehensive and uninterrupted assessment of cardiac output (CO) and oxygen delivery (DO2). At present, hemodynamic monitors offer uninterrupted analysis of blood pressure data but depend on occasional data from other monitors for oxygenation, therefore providing clinicians with only partial knowledge.

Hemodynamic Monitoring System Market Trends

• Rise in the geriatric population and new developments are driving the market growth

The rise in the number of elderly patients who are critically ill, the prevalence of heart illnesses and diabetes, the demand for home-based and non-invasive monitoring systems, and the rise in the number of hypertensive patients are the main drivers of this market's expansion. According to the World Health Organization's Facts of 2021, 1.28 billion persons globally between the ages of 30 and 79 are thought to have hypertension. According to the same source, cardiovascular diseases (CVDs) account for an estimated 17.9 million deaths annually, or 32% of all fatalities worldwide, making them the top cause of death globally. According to the American Heart Association, approximately 69.0% of persons experiencing cardiac arrest and 77.0% of people experiencing strokes for the first time report blood pressure readings higher than 140/90 mm Hg. As a result, monitoring blood pressure using these devices aids in the prevention and early identification of cardiovascular disease. As a result, the prevalence of cardiovascular diseases and hypertension will probably promote market expansion.

As they offer precise and repeatable measurements that can be used to detect hemodynamic alterations and their causes, optimize hemodynamic conditions like oxygen delivery to the tissues, and provide feedback on the efficacy of therapeutic interventions, new techniques of hemodynamic monitoring have the potential to advance the management of the cardiovascular patient during postoperative care and anesthesia. The switch to less invasive or non-invasive monitoring techniques and the shift from static to dynamic variables for assessing requirements like cardiac preload and fluid responsiveness are further propelling the market's expansion.

Hemodynamic Monitoring System Market Segment Insights

Hemodynamic Monitoring System Product Insights

Based on product, the global hemodynamic monitoring system segmentation includes disposables, monitors, minimally invasive and others. The disposables segment held the majority share of around 60% in 2022. Other sub-categories of disposables include airflow sensors, probes, circuits, and others. The need for disposables is anticipated to rise as hemodynamic monitoring products are used more frequently in emergency and trauma rooms. As invasive catheters used to measure arterial pressure must be changed after each patient, the market for these catheters is expected to expand.

Hemodynamic Monitoring System Type Insights

Based on type, the global hemodynamic monitoring system segmentation includes invasive, non-invasive and others. The invasive segment had the largest share of the hemodynamic monitoring system market in 2022 and is expected to increase the market growth. The invasive segment of the market is anticipated to be driven by rising rates of arrhythmias and pulmonary hypertension.

The term "minimally invasive devices" refers to all equipment and techniques, such as esophageal Doppler, pulse pressure analysis, thoracic electrical bio-impedance, and echocardiography, that aid in assessing cardiac output without the need for catheter insertion.

Due to increased product development and growing patient demand, non-invasive devices will experience the greatest growth throughout the projection period. Non-invasive technologies enable the internal evaluation of hemodynamic statistics without sacrificing precision and dependability.

For instance, Edward Lifesciences' Nexfin measures artery pressure by wrapping the patient's finger in a cuff. A co-oximeter is a feature of a different variation called Nexfin CO-Trek that enables the assessment of the oxygen delivery index (DO2I).

Figure 1: Hemodynamic Monitoring System Market by Type, 2022 & 2030 (USD billion)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Hemodynamic Monitoring System End User Insights

Based on end users, the global hemodynamic monitoring system segmentation includes hospitals, clinics, ambulatory care centers, home care settings and others. Hospitals held over 40% of the market in 2022, and it is anticipated that they would continue to dominate during the projected period.

Nonetheless, their use in clinics, home care settings, and ambulatory services is predicted to increase as a result of the development of several non-invasive and portable monitoring systems that are highly patient-compliant. Hence, these end users make up the most lucrative market and are anticipated to have faster growth.

Hemodynamic Monitoring System Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America's hemodynamic monitoring system market accounted for USD 0.34 billion in 2022. In 2022, North America was responsible for around 35.0% of the global market for hemodynamic monitoring devices. Sales of these systems in the United States have been strong. It is projected that this dominance will be maintained over the next eight years thanks to doctors' and clinical staff's growing faith in emerging non-invasive technology. Additionally, the recent FDA clearance of goods like ClearSight is anticipated to increase sales during the projected period.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, Africa, the Middle East, and Latin America. 

Figure 3: GLOBAL HEMODYNAMIC MONITORING SYSTEMMARKET SHARE BY REGION 2022 (%)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's hemodynamic monitoring system market accounts for a significant market share due to the increased prevalence of cardiovascular diseases and the growing number of seniors who need critical care. Further, the German hemodynamic monitoring system market held the largest market share, and the UK hemodynamic monitoring system market was the fastest-growing market in the European Region.

The Asia-Pacific hemodynamic monitoring system market is expected to grow at the fastest CAGR in the forecast period from 2022 to 2030. Because of the increasing governmental emphasis on high-quality healthcare, the Asia Pacific area is seen as having the best prospects over the next five years. Moreover, the China hemodynamic monitoring system market held the largest market share, and the Indian hemodynamic monitoring system market was the fastest-growing in Asia-Pacific.

Hemodynamic Monitoring System Key Market Players & Competitive Insights

Leading market players invest a lot of money in research and market development to expand their product offerings, which raises the hemodynamic monitoring system industry. To expand their global presence and respond to important industry developments, market participants take strategic activities like introducing new products, contractual agreements, mergers and acquisitions, increased investments, and collaborations with other businesses. If they want to grow and be successful, competitors in the hemodynamic monitoring system industry must provide items at fair costs.

One of the main business strategies adopted by manufacturers in hemodynamic monitoring system industry to satisfy customers and expand the market sector is local production to lower operational costs. The major hemodynamic monitoring system markets players, such as Edwards Lifesciences Corporation, Getinge AB, Baxter International Inc., Drägerwerk AG & Co. KGaA, and others, are working on expanding the market demand by investing in research and development activities.

A medical technology firm with its main office in Irvine, California, Edwards Lifesciences is American and focuses on hemodynamic monitoring and prosthetic heart valves. It created the balloon-expandable, cobalt-chromium SAPIEN transcatheter aortic heart valve, constructed of bovine tissue and placed by catheter. The business includes manufacturing facilities at Irvine headquarters in Draper, Utah, Costa Rica, the Dominican Republic, Puerto Rico, and Singapore. It is also constructing a new facility in Limerick, Ireland, scheduled to be finished in 2021. On August 16, 2019, the FDA approved using Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve Systems for treating patients with a low risk of death or serious complications following open-heart surgery. These treatments avoid open cardiac surgery and are used on individuals with severe aortic stenosis.

A multinational medical technology provider, Getinge was established in Sweden in 1904. The company offers systems and equipment for the life sciences and healthcare industries. The company had previously been divided into three business divisions: Infection Control (trading as Getinge), Extended Care (ArjoHuntleigh), and Medical Systems (Maquet, the largest manufacturer of surgical tables in the world). On March 20, 2017, the company announced it would merge into a single-brand company and begin operating under Getinge. Carl Bennet and Rune Andersson bought it in 1989. Since July 2009, Getinge's equities have been listed on the OMXS30 Index and traded on the Stockholm Stock Exchange since 1993. Mattias Perjos serves as the organization's president and CEO. The organization's chairman is Johan Malmquist. Getinge's shares have been traded since 1993 on the OMX Nordic List in Stockholm, and since July 2009, they have been included in the OMXS30 Index. Getinge bought the American business Atrium Medical in 2011 and Pulsion Medical Systems in 2014.

Key Companies in the hemodynamic monitoring system market include

• Edwards Lifesciences Corporation


• Getinge AB


• Baxter International Inc.


• Drägerwerk AG & Co. KGaA


• LiDCO Group


• Osypka Medical GmbH


• Deltex Medical


• ICU Medical


• CNSYSTEMS MEDIZINTECHNIK GMBH


• NI Medical, among others

Hemodynamic Monitoring System Industry Developments

February 2022: The US Food and Drug Administration (FDA) granted Breakthrough Device Designation to Noninvasix's LIVOx Central Venous Oxygenation Monitor for non-invasive, real-time, continuous, or spot monitoring of central venous oxygen saturation (ScvO2) in people at risk of septic shock.

January 2022: Sensydia, a pioneer in the quick, non-invasive monitoring of vital heart function, declared that the US Food and Drug Administration had designated its Cardia Performance System (CPSTM) as a breakthrough device (FDA).

Hemodynamic Monitoring System Market Segmentation

Hemodynamic Monitoring System Type Outlook

• Invasive


• Non-invasive


• Others

Hemodynamic Monitoring System Product Outlook

• Disposables


• Monitors


• Minimally Invasive


• Others

Hemodynamic Monitoring System End User Outlook

• Hospitals


• Clinics


• Ambulatory Care Centers


• Home Care Settings


• Others

Hemodynamic Monitoring System Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America